HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit

Atherosclerosis

Volumn 139, Issue 1, 1998, Pages 21-30

  Bocan, Thomas M a ^a   Bak Mueller, Sandra ^a   Quenby Brown, Edie ^a   Lee, Peter ^a   Bocan, Michelle J ^a   Rea, Thomas ^a   Pape, Michael E ^a  

^a PFIZER INC   (United States)

Author keywords

ACAT; Atherosclerosis; HMG CoA reductase; Hypercholesterolemia; Rabbit

Indexed keywords

2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; DRUG POTENTIATION; FAT INTAKE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME;

ANIMALS; ARTERIOSCLEROSIS; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DRUG SYNERGISM; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RABBITS; STEROL O-ACYLTRANSFERASE;

EID: 0032126266     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00046-X     Document Type: Article

References (49)

1. Brown M.S., Goldstein J.L. A receptor mediated pathway for cholesterol homeostasis. Science. 232:1986;34.
2. Kovanen P.T., Bilheimer D.W., Goldstein J.L., Jaramillo J.J., Brown M.S. Regulatory role of hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA. 78:1981;1194.
3. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 80:1983;4124.
4. Arad Y., Ramakrishnan R., Ginsberg H.N. Effects of lovastatin therapy on very low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41:1992;487.
5. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscl Thromb Vascl Biol. 15:1995;678.
6. Walker J.F. HMG-CoA reductase inhibitors. Current clinical experience. Drugs. 36:1988;83.
7. McTavish D., Sorkin E.M. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 42:1991;65.
8. Todd P.A., Goa K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 40:1990;583.
9. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383.
10. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301.
11. Kritchevsky D., Tepper S.A., Klurfeld D.M. Influence of mevinolin on experimental atherosclerosis in rabbits. Pharmacol Res Commun. 13:1981;921.
12. Kobayaski M., Ishida F., Takahashi T., Kobayashi M., Ishida F., Takahashi T., Taguchi K., Watanabe K., Ohmura I., Kamei T. Preventive effect of MK-733 (Simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol. 49:1989;125.
13. Zhu B.Q., Sievers R.E., Sun Y.P., Isenberg W.M., Parmley W.W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmol. 19:1992;246.
14. Shiomi M., Ito T., Watanabe Y., Tsujita Y., Kuroda M., Arai M., Fukami M., Fukushige J., Tamura A. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine. Atherosclerosis. 83:1990;69.
15. Bocan T.M.A., Mazur M.J., Bak-Mueller S., Quenby-Brown E., Sliskovic D.R., O'Brien P.M., Creswell M.W., Lee H., Uhlendorf P.D., Roth B.D., Newton R.S. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation. Atherosclerosis. 111:1994;127.
16. Krause BR, Bocan TMA. ACAT inhibitors: Physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals. In: Ruffolo RR, Hollinger MA, editors. Inflammation, Mediators, and Pathways. Boca Raton, FL: CRC Press 1995:173.
17. Bocan T.M.A., Bak-Mueller S., Uhlendorf P.D., Newton R.S., Krause B.R. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological and morphometric evaluation. Arterioscler Thromb. 11:1991;1830.
18. Roth B.D., Blankley C.J., Chucholowski A.W., Ferguson E., Hoefle M.L., Ortwine D.F., Newton R.S., Sekerke C.S., Sliskovic D.R. Inhibitors of cholesterol biosynthesis. 3. tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J Med Chem. 34:1991;357.
19. Roth B.D., Blankley C.J., Hoefle M.L., Holmes A., Roark W.H., Trivedi B.K., Essenburg A.D., Kieft K.A., Krause B.R., Stanfield R.L. Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents. J Med Chem. 35:1992;1609.
20. Allain C.C., Poon L.S., Chan C.S.G., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470.
21. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19:1973;476.
22. Kieft K.A., Bocan T.M.A., Krause B.R. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J Lipid Res. 32:1991;859.
23. Cooper GR. Cholesterol: enzymatic methods. In: Faulkner WR, Meiters S, editors. Selected Methods for the Small Clinical Chemistry Laboratory. Washington, DC: American Association of Clinical Chemists, 1982:165.
24. Bocan T.M.A., Bak Mueller S., Uhlendorf P.D., Ferguson E., Newton R.S. Dietary and mechanically induced rabbit iliac-femoral atherosclerotic lesions. Exp Mol Pathol. 54:1991;210.
25. Folch J., Lees M., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 226:1957;497.
26. Pape M.E., Marotti K.R., Melchior G.W. An improved method for precise quantitation of cellular and tissue apolipoprotein A-I mRNA levels by use of an internal standard. J Lipid Res. 31:1990;727.
27. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156.
28. Rea T.J., DeMattos R.B., Pape M.E. Hepatic expression of genes regulating lipid metabolism in rabbits. J Lipid Res. 34:1993;1901.
29. Pape M.E., Melchior G.W., Marotti K.R. mRNA quantification by a simple and sensitive RNAse protection assay. Genetic Analysis Techniques. 8:1991;206.
30. Thompson SW. Selected Histochemical and Histopathological Methods. Springfield, IL: Thomas, 1966.
31. Tsukada T., Rosenfeld M., Ross R., Gown A.M. Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis. 6:1985;601.
32. Gown A.M., Vogel A.M., Gordon D., Lu P.L. A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes. J Cell Biol. 100:1985;807.
33. Ott L. An Introduction to Statistical Methods and Data Analysis. North Scituate, MA: Duxbury Press, 1977.
34. Shanks ME, Gambill R. Calculus Analytic Geometry/Elementary Functions. New York: Holt, Rinehart and Winston, 1973.
35. Bocan T.M.A., Ferguson E., McNally W., Uhlendorf P.D., Bak Mueller S., Dehart P., Sliskovic D.R., Roth B.D., Krause B.R., Newton R.S. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1123:1992;133.
36. Gillies P.J., Robinson C.S., Rathgeb K.A. Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: implications for drug discovery. Atherosclerosis. 83:1990;177.
37. Ishida F., Sata A., Iizuka Y., Kamei T. Inhibition of acyl coenzyme A: cholesterol acyltransferase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Chem Pharm Bull. 37:1989;1635.
38. Carr T.P., Hamilton R.L., Rudel L.L. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res. 36:1995;25.
39. Huff M.W., Telford D.E., Barrett H.R., Billheimer J.T., Gillies P.J. Inhibition of hepatic ACAT decreases Apo B secretion in miniature pigs fed a cholesterol-free diet. Arterioscl Thromb. 14:1994;1498.
40. Tanaka M., Jingami H., Otani H., Cho M., Ueda Y., Arai H., Nagano Y., Doi T., Yokode M., Kita T. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J Biol Chem. 268:1993;12713.
41. Krause B.R., Anderson M., Bisgaier C.L., Bocan T., Bousley R., DeHart P., Essenburg A., Hamelehle K., Homan R., Kieft K., McNally W., Stanfield R., Newton R.S. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res. 34:1993;279.
42. Hoang V., Botham K.M., Benson G.M., Eldredge E.E., Jackson B., Pearce N., Suckling K.E. Bile acid synthesis in hamster hepatocytes in primary culture: sources of cholesterol and comparison with other species. Biochim Biophys Acta. 1210:1993;73.
43. Grogan W.M., Bailey M.L., Heuman D.M., Vlahcevic Z.R. Effects of pertubations in hepatic free and esterified cholesterol pools on bile acid synthesis, cholesterol 7α-hydroxylase, HMG-CoA reductase, acyl-CoA:cholesterol acyltransferase and cytosolic cholesteryl ester hydrolase. Lipids. 26:1991;907.
44. Krause B.R., Pape M.E., Kieft K., Auerbach B., Bisgaier C.L., Homan R., Newton R.S. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscl Thromb. 14:1994;598.
45. Puglielli L., Rigotti A., Amigo L., Nunez L., Greco A.V., Santos M.J., Nervi F. Modulation of intrahepatic cholesterol trafficking: evidence by in vivo antisense treatment for the involvement of sterol carrier protein-2 in newly synthesized cholesterol transport into rat bile. Biochem J. 317:1996;681.
46. Hapala I., Kavecansky J., Butko P., Scallen T.J., Joiner C.H., Schroeder F. Regulation of membrane cholesterol domains by sterol carrier protein-2. Biochemistry. 33:1994;7682.
47. Levin M.S., Pitt A.J.A., Schwartz A.L., Edwards P.A., Gordon J.I. Developmental changes in the expression of genes involved in cholesterol biosynthesis and lipid transport in human and rat fetal and neonatal livers. Biochim Biophys Acta. 1003:1989;293.
48. Geelan M.J.H., Beynen A.C., Wirtz K.W.A. Cholesterol metabolism and sterol carrier protein-2 (nonspecific lipid transfer protein). J Biochem. 19:1987;619.
49. Baum C.L., Kansal S., Davidson N.O. Regulation of sterol carrier protein-2 gene expression in rat liver and small intestine. J Lipid Res. 34:1993;729.